Endralazine (BioDeep_00000178699)

   

human metabolite blood metabolite


代谢物信息卡片


(3Z)-6-benzoyl-3-hydrazinylidene-2H,3H,5H,6H,7H,8H-pyrido[4,3-c]pyridazine

化学式: C14H15N5O (269.127654)
中文名称: 恩屈嗪
谱图信息: 最多检出来源 Mus musculus(blood) 50%

分子结构信息

SMILES: C1CN(CC2=CC(=NN=C21)NN)C(=O)C3=CC=CC=C3
InChI: InChI=1S/C14H15N5O/c15-16-13-8-11-9-19(7-6-12(11)17-18-13)14(20)10-4-2-1-3-5-10/h1-5,8H,6-7,9,15H2,(H,16,18)

描述信息

C - Cardiovascular system > C02 - Antihypertensives > C02D - Arteriolar smooth muscle, agents acting on > C02DB - Hydrazinophthalazine derivatives
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

同义名列表

7 个代谢物同义名

(3Z)-6-benzoyl-3-hydrazinylidene-2H,3H,5H,6H,7H,8H-pyrido[4,3-c]pyridazine; 6-Benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido- (4,3-c)pyridazine mesylate; (3Z)-6-benzoyl-3-hydrazinylidene-2H,5H,7H,8H-pyrido[4,3-c]pyridazine; BQ 22-708, mono-Methanesulfonate; BQ 22-708, Methanesulfonate; ENDRALAZINE; Miretilan



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • J Kindler, P C Rüegg, M Neuray, W Pacha. Effect of food intake on plasma levels and antihypertensive response during maintenance therapy with endralazine. European journal of clinical pharmacology. 1987; 32(4):367-72. doi: 10.1007/bf00543971. [PMID: 3609114]
  • J H Hauger-Klevene, C Reader, E Mayer, M R Sanchez. A comparative study of endralazine and captopril in essential hypertension: effect on renin levels, pulmonary function studies and lipid profile. International journal of clinical pharmacology research. 1986; 6(4):275-81. doi: NULL. [PMID: 3531038]
  • H L Elliott, P A Meredith, J L Reid. Pharmacodynamic and pharmacokinetic studies with the vasodilator endralazine. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1984 Dec; 2(3):S551-4. doi: NULL. [PMID: 6599716]
  • H L Elliott, P A Meredith, L Sloan, J L Reid. Clinical pharmacological studies with the vasodilator endralazine in patients with renal impairment. European journal of clinical pharmacology. 1984; 27(2):159-63. doi: 10.1007/bf00544039. [PMID: 6499896]
  • M D Donaldson, T L Chambers. Endralazine in treatment of hypertension in children with renal disease. Lancet (London, England). 1983 Sep; 2(8350):635. doi: 10.1016/s0140-6736(83)90727-4. [PMID: 6136791]
  • J J Hoffmann, T Thien, A van T'Laar. Effects of intravenous endralazine in essential hypertension. British journal of clinical pharmacology. 1983 Jul; 16(1):39-44. doi: 10.1111/j.1365-2125.1983.tb02141.x. [PMID: 6349669]
  • P A Reece, I Cozamanis, R Zacest. Endralazine - a new hydralazine-like antihypertensive with high systemic bioavailability. European journal of clinical pharmacology. 1983; 25(4):553-6. doi: 10.1007/bf00542127. [PMID: 6653651]
  • E Wegmüller, F C Reubi. Changes in renal function induced by endralazine, a new antihypertensive drug. European journal of clinical pharmacology. 1983; 24(3):307-14. doi: 10.1007/bf00610046. [PMID: 6345175]
  • J C Kingswood, P R Harrison, R A Banks, E Higgs, J C Mackenzie. Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension. Postgraduate medical journal. 1983; 59 Suppl 3(?):173-6. doi: NULL. [PMID: 6647204]
  • E R Higgs, P R Harrison, R A Banks, J C Kingswood, J C Mackenzie. Endralazine in patients with severe hypertension and renal insufficiency. Postgraduate medical journal. 1982 Dec; 58(686):767-70. doi: 10.1136/pgmj.58.686.767. [PMID: 6984902]
  • S de Flora, P Zanacchi, C Bennicelli, A Camoirano, M Cavanna, L Sciabà, E Cajelli, P Faggin, G Brambilla. In vivo and in vitro genotoxicity of three antihypertensive hydrazine derivatives (hydralazine, dihydralazine, and endralazine). Environmental mutagenesis. 1982; 4(5):605-19. doi: 10.1002/em.2860040512. [PMID: 7140679]
  • H L Elliott, K McLean, D J Sumner, R J Donnelly, J L Reid. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension. Clinical and experimental hypertension. Part A, Theory and practice. 1982; 4(8):1409-18. doi: 10.3109/10641968209060798. [PMID: 6749347]
  • P A Reece, I Cozamanis, R Zacest. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine. European journal of clinical pharmacology. 1982; 23(6):523-7. doi: 10.1007/bf00637500. [PMID: 7160421]
  • P A Reece, I Cozamanis, R Zacest. Sensitive high-performance liquid chromatographic assay for endralazine and two of its metabolites in human plasma. Journal of chromatography. 1981 Sep; 225(1):151-60. doi: 10.1016/s0378-4347(00)80254-6. [PMID: 7298742]
  • H F Oates, L M Stoker. Studies in the rat on endralazine, a new antihypertensive drug structurally related to hydralazine. Clinical and experimental pharmacology & physiology. 1981 Mar; 8(2):133-9. doi: 10.1111/j.1440-1681.1981.tb00144.x. [PMID: 7018762]
  • R Salzmann, H Bürki, D Chu, B Clark, P Marbach, R Markstein, H Reinert, H Siegl, R Waite. [Pharmacologic effects of the antihypertensive 6-benzoyl-3-hydrazino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazine (BQ 22-708, endralazine)]. Arzneimittel-Forschung. 1979; 29(12):1843-53. doi: NULL. [PMID: 232662]